Effects of Psychostimulant Drugs on Developing Brain

Objective & Hypothesis:Although psychostimulants have been used for the treatment of attention deficit hyperactivity disorder for approximately 70 years, little is known about the long term effects of these drugs on developing brain.

📊

Key Findings & Data:The observable effects of psychostimulants are influenced by the timing of exposure, the age of examination after drug exposure and sex.

💡

Conclusion & Impact:The aim of this paper is to review the effects of psychostimulants on developing brain.

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Psikostimülan · gelişen beyin · dikkat eksikliği hiperaktivite bozukluğu

Abstract

Although psychostimulants have been used for the treatment of attention deficit hyperactivity disorder for approximately 70 years, little is known about the long term effects of these drugs on developing brain. The observable effects of psychostimulants are influenced by the timing of exposure, the age of examination after drug exposure and sex. Preclinical studies point out that chronic psychostimulant exposure before adolescence cause reverse sensitization or tolerance and this leads to reduction in stimulant effectiveness in adolesecence and adulthood. Preclinical studies show the potential long term effects of psychostimulants. But it is necessary to investigate the relationship between preclinical effects and clinical practice. A developmental approach is needed to understand the impact of pediatric medications on the brain that includes assessment at multiple ages to completely characterize the long term effects of these medications. The aim of this paper is to review the effects of psychostimulants on developing brain.

Özet

Psikostimülanlar dikkat eksikliği hiperaktivite bozukluğu tedavisinde yaklaşık 70 yıldır kullanılmasına rağmen, bu ilaçların gelişen beyin üzerindeki uzun dönem etkileri hakkında çok az şey bilinmektedir. Psikostimülanların saptanan etkileri maruziyetin zamanı, yapılan değerlendirmenin zamanı ve cinsiyetten etkilenmektedir. Preklinik çalışmalar, ergenlik öncesinde kronik stimülan maruziyetinin ters duyarlılaşma veya tolerans oluşmasına yol açtığı ve bunun da ergenlik ve sonrasında stimulanların etkinliğinde azalmaya yol açacağına işaret etmektedir. Preklinik çalışmalar psikostimülanların uzun dönem etkileri olabileceğine işaret etmektedir. Ancak bu olası etkilerin klinik olarak hangi düzeyde olabileceğinin araştırılması gerekmektedir. Psikostimülan ilaçların beyin üzerindeki etkilerini daha iyi anlamak için farklı yaş gruplarında yapılacak çalışmalara gereksinim olduğu düşünülmektedir..

Keywords

Psikostimülan gelişen beyin dikkat eksikliği hiperaktivite bozukluğu Psychostimulant developing brain attention deficit hyperactivity disorder.

🔖

Cite This Article

Durukan, İ., Erdem, M., Kara, K., Karaman, D. (2013). Effects of Psychostimulant Drugs on Developing Brain. Psikiyatride Güncel Yaklaşımlar, Cilt: 5 - Sayı: 4, 528–539. https://ajindex.com/articles/230066

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997; 36:754–763. Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatr Clin North Am 1998; 45:1085–1098.
Henry CA, Zamvil LS, Lam C, Rosenquist KJ, Ghaemi SN. Long-term outcome with divalproex in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2003; 13:523–529.
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003: 27, 85–102. Minde K. The use of psychotropic medication in preschoolers: some recent developments. Can J Psychiatry 1998; 43:571–575.
Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. J Am Med Assoc 2000; 283:1025–1030.
Goodwin R, Gould MS, Blanco C, Olfson M. Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv 2001; 52:1081–1087.
Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002; 41:514–521.
Costello EJ, Pine DS, Hammen C, March JS, Plotsky PM, Weissman MM et al. Development and natural history of mood disorders. Biol Psychiatry 2002; 52:529– 5 Greenfield B, Hechtman L, Weiss G. Two subgroups of hyperactives as adults: correlations of outcome. Can J Psychiatry 1988; 33:505–508.
Greene RW, Biederman J, Faraone SV, Wilens TE, Mick E, Blier HK. Further validation of social impairment as a predictor of substance use disorders: findings from a sample of siblings of boys with and without ADHD. J Clin Child Psychol 1999; 28:349–354.
Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention deficit hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104:e20. Wilens TE, Biederman J, Millstein RB, Wozniak J, Hahesy AL, Spencer TJ. Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:680–685. Ryan ND. Child and adolescent depression: short-term treatment effectiveness and long-term opportunities. Int J Methods Psychiatr Res 2003; 12:44–53. Spear L. The adolescent brain and age-related behavioral manifestations. Neurosci Bio-Behav Rev 2000; 24:417–463. Slotki